07:00 , Aug 4, 2014 |  BC Week In Review  |  Company News

Aptiv Solutions, Eli Lilly, J&J, Novartis, Pfizer, Roche other news

Pfizer and Roche joined the ADDPLAN DF consortium, which is seeking to develop new statistical methods for the design of dose-finding trials. The consortium will hold a public meeting on Aug. 4 to discuss its...
01:12 , Aug 2, 2014 |  BC Extra  |  Politics & Policy

Pfizer and Roche join ADDPLAN DF consortium

Pfizer Inc. (NYSE:PFE) and Roche (SIX:ROG; OTCQX:RHHBY) joined the ADDPLAN DF consortium, which is seeking to develop new statistical methods for designing dose-finding trials. Aptiv Solutions (Reston, Va.), Eli Lilly and Co. (NYSE:LLY), Johnson &...
08:00 , Feb 24, 2014 |  BioCentury  |  Product Development

Dosing certainty

Novartis AG has developed a new dosing model for Phase II trials that eliminates much of the guesswork around dose selection for Phase III. EMA has endorsed the model and the pharma is in discussions...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Company News

Aptiv Solutions, EMA, U.S. Food and Drug Administration deal

U.S. Food and Drug Administration (FDA) purchased a license to Aptiv's ADDPLAN DF software for analysis of dose-finding study results submitted as part of approval applications to the agency's Center for Drug Evaluation and Research...
07:00 , Apr 4, 2011 |  BC Week In Review  |  Company News

Aptiv Solutions supply/service news

Aptiv also hired Michael McKelvey as EVP and COO. McKelvey was formerly president and CEO at CRO eResearch Technology Inc. (Philadelphia, Pa.). Aptiv Solutions, Great Falls, Va.   Business: Supply/Service   New CRO Aptiv Solutions was...
07:00 , Sep 20, 2010 |  BC Week In Review  |  Company News

Addplan GmbH, Averion, ClinResearch GmbH, Fulcrum, Trio Clinical Research LLC deal

The companies merged to form a new entity to provide drug and device development services. The merger was led by a group of investors, including SV Life Sciences, The Halifax Group and the Comvest Group....